Nektar Therapeutics (NKTR) Equity Ratio (2010 - 2026)

Nektar Therapeutics' Equity Ratio history runs 17 years deep, the most recent figure standing at 0.75 for Q1 2026.

• In Q1 2026, Equity Ratio rose 1308.09% year-over-year to 0.75; the TTM figure through Mar 2026 stood at 0.75 (up 1308.09% YoY), while the FY2025 annual figure was 0.32, up 60.27% from the prior year.
• Equity Ratio was 0.75 for Q1 2026 at Nektar Therapeutics, up from 0.32 in the prior quarter.
• In the past five years, Equity Ratio ranged from a high of 0.75 in Q1 2026 to a low of 0.12 in Q2 2025.
• Historically, Equity Ratio has averaged 0.35 across 5 years, with a median of 0.33 in 2023.
• The sharpest annual moves came in 2025 and 2026: Equity Ratio slumped 150.26% in 2025, then surged 1308.09% in 2026.
• A 5-year view of Equity Ratio shows it stood at 0.52 in 2022, then plunged by 36.22% to 0.33 in 2023, then plunged by 39.26% to 0.2 in 2024, then jumped by 60.27% to 0.32 in 2025, then jumped by 135.65% to 0.75 in 2026.
• The last three Equity Ratio figures came in at 0.75 (Q1 2026), 0.32 (Q4 2025), and 0.28 (Q3 2025), per Business Quant data.